NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Drug Manufacturers - Specialty & Generic · USD

Zoetis Inc. (ZTS) Stock Analysis

Zoetis Inc. (ZTS) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

ZTS

$79.62

−$0.42 (−0.52%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ZTS with… →

ZTS Key Statistics

As of Oct 21, 2026
Trading
Open
$79.22
Previous Close
$80.04
Day's Range
78.88–80.00
52-Week Range
68.77–148.30
Volume
3.03M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.74
Valuation
Market Cap
$32.90B
P/E Ratio
13.10
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
12.16
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
14.90
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.45
EPS (ttm)Profit attributable to each share over the last twelve months.
6.08
Financials (FY)
Revenue (FY)
$9.47B+2.28%
Net Income (FY)
$2.67B+7.52%
Profit marginThe share of revenue left as profit after all costs and taxes.
27.69%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
413.22M
1-Year Return
−44.45%
Dividend and dates
Dividend
$2.12+2.65%
Ex-Dividend Date
October 30, 2026
Earnings Date
November 5, 2026
Avg Volume
5.21M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ZTS closed at $79.62, −44.45% over 1 year.

Zoetis Inc. (ZTS) has a market capitalization of $32.90B.

In fiscal 2025, ZTS reported revenue of $9.47B.

ZTS Stock Return by Calendar Year

Zoetis Inc. (ZTS) 10-year return: what $10,000 became

1 year
$10,000 $5,555
−44.45%
5 years
$10,000 $4,037
−59.63%
10 years
$10,000 $17,062
+70.62%

If you had invested $10,000 in Zoetis Inc. (ZTS) 10 years ago, at the close on October 21, 2016, it would have been worth $17,062 at the close on October 21, 2026: +70.62% in total, +5.49% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−35.73%
2025−21.75%
2024−16.63%
2023+35.91%
2022−39.51%
2021+48.26%
2020+25.76%
2019+55.71%
2018+19.45%
2017+35.55%
2016 (partial year)+5.58%

As of October 21, 2026.

ZTS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$9.47B$2.67B28.2%
2024$9.26B$2.49B26.9%
2023$8.54B$2.34B27.4%
2022$8.08B$2.11B26.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$9.47B$6.80B$3.60B$2.67B28.2%
2024$9.26B$6.54B$3.39B$2.49B26.9%
2023$8.54B$5.98B$3.07B$2.34B27.4%
2022$8.08B$5.63B$2.93B$2.11B26.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ZTS Dividend History

$2.00+15.7% vs 2024

Dividends per share, 2025 · 4 payments

YearDividends per sharePaymentsChange
2026*$1.593—
2025$2.004+15.7%
2024$1.734+15.2%
2023$1.504+15.4%
YearDividends per sharePaymentsChange
2026 (partial year)$1.593—
2025$2.004+15.7%
2024$1.734+15.2%
2023$1.504+15.4%
2022$1.304+30.0%
2021$1.004+25.0%
2020$0.804+22.0%
2019$0.664+30.2%
2018$0.504+20.0%
2017$0.424+342.1%
2016$0.101—

Most recent payment: $0.53 per share, ex-dividend July 20, 2026. Per-share amounts summed by calendar year from ex-dividend dates. Partial years are shown muted and marked with an asterisk.

ZTS Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricZTSDrug Manufacturers - Specialty & Generic medianvs median
P/E13.1020.3136% below
P/S ratio3.452.1064% above
Profit margin27.69%−8.14%35.8 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Zoetis Inc. (ZTS) carries a market capitalisation of $32.90B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 14,500 employees.

ZTS last closed at $79.62 on October 21, 2026. That is −$0.42 (−0.52%) against the previous close. Over the past 52 weeks the price has ranged from $68.77 to $148.30. The latest close sits 15.78% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $9.47B. That is +2.28% against the prior fiscal year, when revenue was $9.26B. Net income for the same year was $2.67B. That is +7.52% against the prior fiscal year. Profit margin runs at 27.69%. That is 35.8 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to 6.08.

Across the 4 fiscal years on file, revenue moves from $8.08B in 2022 to $9.47B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

ZTS trades at a trailing price-to-earnings ratio of 13.1. That is 35.52% below the Drug Manufacturers - Specialty & Generic median of 20.31. On forward earnings the ratio is 12.16. The PEG ratio, which sets the P/E against expected earnings growth, reads 14.9. Measured against sales, the shares trade at 3.45 times revenue. On price-to-sales that is 64.49% above the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −44.45%. Across 10 years the annualized return works out at +5.49%. The reported beta is 0.74. Daily returns over the trailing 10 years annualize to a volatility of 27.48%.

Growth & Income

ZTS pays a dividend yielding 2.65%. That is 0.5 percentage points above the Drug Manufacturers - Specialty & Generic median yield of 2.17%. The indicated annual rate is $2.12 a share. The ex-dividend date on file is October 30, 2026. Dividends are recorded for 11 calendar years; 2026 shows 3 payments totalling $1.59 a share. The year before, 2025, totalled $2.00 a share.

2026 is still running; the total return is −35.73% year to date. Across the complete calendar years on file, 2019 returned +55.71% and 2022 returned −39.51%. Of the 9 complete calendar years on file, 6 finished higher.

Peer Comparison

Zoetis Inc. (ZTS) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Zoetis Inc. ZTS $32.90B 13.1
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Zoetis Inc. trades at a P/E of 13.1.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B

 NBIX

Neurocrine Biosciences, Inc.

$14.36B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Zoetis Inc.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Visit website →